OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

Diabetes Therapy ◽

10.1007/s13300-016-0184-9 ◽

2016 ◽

Vol 7 (3) ◽

pp. 527-535 ◽

Cited By ~ 1

Author(s):

Shira Perl ◽

William Cook ◽

Cheryl Wei ◽

Nayyar Iqbal ◽

Boaz Hirshberg

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment

Diabetes ◽

10.2337/db20-136-lb ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 136-LB

Author(s):

DAVID CHERNEY ◽

ELE FERRANNINI ◽

GUILLERMO E. UMPIERREZ ◽

ANNE L. PETERS ◽

JULIO ROSENSTOCK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Diabetes Care ◽

10.2337/dc14-2883 ◽

2015 ◽

pp. dc142883 ◽

Cited By ~ 14

Author(s):

Melanie J. Davies ◽

Stephen C. Bain ◽

Stephen L. Atkin ◽

Peter Rossing ◽

David Scott ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Renal Impairment ◽

Randomized Clinical Trial ◽

Efficacy And Safety ◽

Glucose Lowering ◽

Lowering Therapy ◽

Glucose Lowering Therapy

Efficacy and Safety of Liraglutide vs. Placebo as Add-On to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL)

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2014.07.020 ◽

2014 ◽

Vol 38 (5) ◽

pp. S9-S10 ◽

Cited By ~ 2

Author(s):

Phuong Ngo ◽

Melanie Davies ◽

Stephen Atkin ◽

Stephen Bain ◽

Peter Rossing ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Efficacy And Safety ◽

Diabetes Medication

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30192-5 ◽

2019 ◽

Vol 7 (7) ◽

pp. 515-527 ◽

Cited By ~ 46

Author(s):

Ofri Mosenzon ◽

Thalia Marie Blicher ◽

Signe Rosenlund ◽

Jan W Eriksson ◽

Simon Heller ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13413 ◽

2018 ◽

Vol 20 (11) ◽

pp. 2532-2540 ◽

Cited By ~ 45

Author(s):

Paola Fioretto ◽

Stefano Del Prato ◽

John B. Buse ◽

Ronald Goldenberg ◽

Francesco Giorgino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Renal Impairment ◽

Chronic Kidney Disease Stage ◽

Disease Stage ◽

1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

Diabetes ◽

10.2337/db19-1004-p ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 1004-P ◽

Cited By ~ 1

Author(s):

OFRI MOSENZON ◽

SIGNE ROSENLUND ◽

JAN W. ERIKSSON ◽

SIMON R. HELLER ◽

RICHARD E. PRATLEY ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Moderate Renal Impairment

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

International Journal of Clinical Practice ◽

10.1111/ijcp.12322 ◽

2013 ◽

Vol 67 (12) ◽

pp. 1267-1282 ◽

Cited By ~ 193

Author(s):

J. P. H. Wilding ◽

G. Charpentier ◽

P. Hollander ◽

G. González‐Gálvez ◽

C. Mathieu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Randomised Trial ◽

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

Therapeutics and Clinical Risk Management ◽

10.2147/tcrm.s67076 ◽

2015 ◽

pp. 799 ◽

Cited By ~ 6

Author(s):

Baptist Gallwitz

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Moderate Renal Impairment

Review for "Efficacy and safety of once‐weekly semaglutide vs once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes ( SUSTAIN China): a 30‐week double‐blind, phase 3a, randomised trial"

10.1111/dom.14232/v2/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily